United States
Company name: Je Dois L’avoir Boutique
Brand name: 365 Skinny
Product recalled: High Intensity Pills and Emergency Boutique
Reason of the recall: Product contains sibutramine
FDA Recall date: August 02, 2021
Recall details: Hanford, California, Je Dois L’avoir Boutique is voluntarily recalling all of the 365 Skinny High Intensity Pills and or 365 Skinny Emergency Boutique, 30 day capsules supply to the retail/consumer level. The 365 Skinny High Intensity Pills and 365 Skinny Emergency Boutique have been found to contain Sibutramine which is a controlled substance by the DEA and poses significant health risks to consumers both products are from the same manufacturer 365 Skinny is the strongest form and the 365 Skinny Emergency is for people with high blood pressure, diabetes but not limited to other chronic illnesses.
Risk Statement: The 365 Skinny High Intensity Pills and 365 Skinny Emergency Boutique potentially can cause serious health risks such as seizures, tachycardia, palpitations, heart attacks and allergic reactions. Risks associated with this product are more likely with people who have high blood pressure, thyroid disease, men or woman over 65 or children under 16 years old. Je Dois L’avoir Boutique has not received any reports of adverse events related to this recall.
The product is used together with diet and exercise to assist with weight loss and is packaged in bottles of 30 capsules 600mg per capsule. All lots and expiration dates of any of these products are being recalled. Je Dois L’avoir is recalling ALL 365 Skinny High Intensity Pills and 365 Emergency Boutique that it has sold to the public as seen below. Je Dois L’avoir is notifying its distributors and customers by email and is arranging for return/replacement etc. of all recalled products. Consumers that have 365 High Intensity Skinny or 365 Skinny Emergency Boutique which is being recalled should stop using/return to place of purchase/discard/contact Je Dois L’avoir Boutique Immediately.
Check the full recall details on
www.fda.gov
Source: FDA
